Clinical Trial Update: Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of mosunetuzumab and zanubrutinib in relapsed/refractory follicular lymphoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Mosunetuzumab (mosunetuzumab)
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Fondazione Italiana Linfomi - ETS | Conditions: Follicular Lymphoma | Phase 2 | Status: RECRUITING